Scroll Up   
download
print

 

 
 
   
  
% Change: 
Volume: 
52-Week High: 
52-Week Low: 

EVENTS & PRESENTATIONS

BofA Securities Healthcare Conference

Past Events ›

Alnylam Pharmaceuticals Q1 2026 Earnings Conference Call

Past Events ›

Alnylam TTR Investor Webinar

Past Events ›

View all events and presentations ›
container-970 d-flex flex-1

2025 Annual Report

Download

2025 Corporate Responsibility Report

Download

capella

Investor & Scientific Presentations

Explore Capella ›

Investor Toolkit

Quarterly Earnings Presentation - Icon

Q1 2026 Earnings Presentation VIEW PDF ›

10-K - Icon

Latest Form 10-K VIEW PDF ›

10-Q - Icon

Latest Form10-Q VIEW PDF ›

sec-icon

SEC
Filings VIEW All ›

sec-icon

2026 Proxy Statement LEARN MORE ›

View all resources and documents ›

Discover Our Commitment to Patients, Employees, and Our Communities

Corporate Responsibility ›

PRESS RELEASES

Alnylam Issues 2025 Corporate Responsibility Report

Learn More ›

New Data Analyses Presented at Heart Failure 2026 Demonstrate Robust and Consistent Clinical Benefit of Vutrisiran as a First-Line Treatment Option Across ATTR-CM Patient Populations, Including Patients with a High Disease Burden

Learn More ›

Alnylam to Webcast Presentations at Upcoming Investor Conferences

Learn More ›

View all press releases ›